Department of Chemistry, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada.
Environ Sci Process Impacts. 2014 Apr;16(4):672-96. doi: 10.1039/c3em00615h.
This work presents a critical assessment of the state and quality of knowledge around the aquatic photochemistry of human- and veterinary-use pharmaceuticals from laboratory experiments and field observations. A standardized scoring rubric was used to assess relevant studies within four categories: experimental design, laboratory-based direct and indirect photolysis, and field/solar photolysis. Specific metrics for each category are defined to evaluate various aspects of experimental design (e.g., higher scores are given for more appropriate characterization of light source wavelength distribution). This weight of evidence-style approach allowed for identification of knowledge strengths and gaps covering three areas: first, the general extent of photochemical data for specific pharmaceuticals and classes; second, the overall quality of existing data (i.e., strong versus weak); and finally, trends in the photochemistry research around these specific compounds, e.g. the observation of specific and consistent oversights in experimental design. In general, those drugs that were most studied also had relatively good quality data. The four pharmaceuticals studied experimentally at least ten times in the literature had average total scores (lab and field combined) of ≥29, considered decent quality; carbamazepine (13 studies; average score of 31), diclofenac (12 studies; average score of 31), sulfamethoxazole (11 studies; average score of 34), and propranolol (11 studies; average score of 29). Major oversights and errors in data reporting and/or experimental design included: lack of measurement and reporting of incident light source intensity, lack of appropriate controls, use of organic co-solvents in irradiation solutions, and failure to consider solution pH. Consequently, a number of these experimental parameters were likely a cause of inconsistent measurements of direct photolysis rate constants and quantum yields, two photochemical properties that were highly variable in the literature. Overall, the assessment rubric provides an objective and scientifically-defensible set of metrics for assessing the quality of a study. A major recommendation is the development of a method guideline, based on this rubric, for conducting and reporting on photochemical studies that would produce consistent and reliable data for quantitative comparison across studies. Furthermore, an emphasis should be placed on conducting more dual-fate studies involving controlled photolysis experiments in natural sunlight, and whole system fate studies in either natural or artificial systems. This would provide accurate data describing the actual contribution of photolysis to the overall fate of pharmaceuticals in the environment.
本工作对实验室实验和野外观测中人与兽医用药物的水生光化学状态和知识质量进行了批判性评估。使用标准化评分细则对四个类别中的相关研究进行评估:实验设计、基于实验室的直接和间接光解以及野外/太阳光解。为每个类别定义了特定的指标,以评估实验设计的各个方面(例如,更高的分数对应于更合适的光源波长分布特征化)。这种基于证据权重的方法可用于确定涵盖三个方面的知识优势和差距:首先,特定药物和类别的光化学数据的一般程度;其次,现有数据的整体质量(即强与弱);最后,这些特定化合物的光化学研究趋势,例如在实验设计中观察到特定和一致的疏忽。一般来说,研究最多的药物也具有相对较好质量的数据。文献中至少进行了十次实验研究的四种药物的总分(实验室和野外的总和)≥29,被认为是质量不错的;卡马西平(13 项研究;平均得分 31)、双氯芬酸(12 项研究;平均得分 31)、磺胺甲恶唑(11 项研究;平均得分 34)和普萘洛尔(11 项研究;平均得分 29)。数据报告和/或实验设计中的主要疏忽和错误包括:缺乏入射光源强度的测量和报告、缺乏适当的对照、在辐照溶液中使用有机共溶剂以及未能考虑溶液 pH 值。因此,这些实验参数中的许多可能是直接光解速率常数和量子产率测量不一致的原因,这两个光化学性质在文献中变化很大。总体而言,评估细则为评估研究质量提供了一套客观和有科学依据的指标。一个主要建议是制定一种基于该细则的方法指南,用于进行和报告光化学研究,以便为跨研究的定量比较产生一致和可靠的数据。此外,应强调进行更多涉及受控光解实验在自然阳光下的双重命运研究,以及在自然或人工系统中的整体系统命运研究。这将提供准确的数据,描述光解对环境中药物总体命运的实际贡献。